Bionor Pharma is a leading vaccine company, searching for breakthrough treatments for HIV and other deadly viruses.

Modified Peptide based vaccinesen/Vaccines_+_technology/Platform_technology/The key to kill virusen/Vaccines_+_technology/Platform_technology/Vacc-4x kills virus producing cells.en/Vaccines_+_technology/HIV_vaccine_Vacc-4x/

Latest news

Hide mandatory notifications of trade

Bionor Pharma Announces that the Combination of Vacc-4x + Revlimid® is Well Tolerated and Increases CD4 Counts in People Living with HIV

Scientific .2014

(Oslo, Norway, 17 November 2014) Bionor Pharma ASA (OSE:BIONOR) announces the results from the Vacc-4x + Revlimid (lenalidomide) study also known as the “Boost & Kill” study. The Phase II trial was an exploratory double-blind placebo controlled immunogenicity study of Vacc-4x + Revlimid versus Vacc-4x in HIV subjects on ART (HIV standard of care treatment).

Financial Calendar 2015

Financial .2015

The 2015 financial calendar of Bionor Pharma ASA has been scheduled as follows:

Bionor Pharma - Third quarter results 2014

Financial .2014

(Oslo, 04.11.2014) Bionor Pharma ASA (OSE: BIONOR) announced today its financial results for the third quarter 2014 and update on its clinical development program.

Bionor Pharma Announces that the Combination of Vacc-4x + Revlimid® is Well Tolerated and Increases CD4 Counts in People Living with HIV

Scientific .2014

(Oslo, Norway, 17 November 2014) Bionor Pharma ASA (OSE:BIONOR) announces the results from the Vacc-4x + Revlimid (lenalidomide) study also known as the “Boost & Kill” study. The Phase II trial was an exploratory double-blind placebo controlled immunogenicity study of Vacc-4x + Revlimid versus Vacc-4x in HIV subjects on ART (HIV standard of care treatment).

Financial Calendar 2015

Financial .2015

The 2015 financial calendar of Bionor Pharma ASA has been scheduled as follows:

Bionor Pharma - Third quarter results 2014

Financial .2014

(Oslo, 04.11.2014) Bionor Pharma ASA (OSE: BIONOR) announced today its financial results for the third quarter 2014 and update on its clinical development program.

Go to news section

Featured content